Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 0.00% is 100% above its 5-year average of -53.61%, near the high end of its 5-year range (-18062.03%–639.95%).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
-53.61%
NET PROFIT MARGIN AVG 10Y
-257.05%
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
+100.00%
CURRENT VS 10Y AVG
+100.00%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+100.00%
vs the sector median at left
Market Cap
$6.74M
Net Profit Margin
-611.47%
TTM Avg
-627.26%
3Y Avg
-917.71%
5Y Avg
-6297.45%
Market Cap
$7.04M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-287.91%
5Y Avg
-676.70%
Market Cap
$7.07M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-19.45%
5Y Avg
-19.45%
Market Cap
$7.12M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$7.15M
Net Profit Margin
-1977.59%
TTM Avg
-1280.67%
3Y Avg
-1780.71%
5Y Avg
-1415.68%
Market Cap
$6.61M
Net Profit Margin
-84.79%
TTM Avg
-89.20%
3Y Avg
-105.63%
5Y Avg
-91.66%
Market Cap
$6.60M
Net Profit Margin
-1084.23%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$6.60M
Net Profit Margin
-10978.48%
TTM Avg
-12422.83%
3Y Avg
-10763.38%
5Y Avg
-10131.90%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Exicure, Inc. (XCUR) | $6.88M | 0.00% | 0.00% | 0.00% | -53.61% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.74M | -611.47% | -627.26% | -917.71% | -6297.45% |
| KALA BIO, Inc. (KALA)vs › | $7.04M | 0.00% | 0.00% | -287.91% | -676.70% |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.07M | 0.00% | 0.00% | -19.45% | -19.45% |
| Skye Bioscience, Inc. (SKYE)vs › | $7.12M | 0.00% | 0.00% | 0.00% | 0.00% |
| Longeveron Inc. (LGVN)vs › | $7.15M | -1977.59% | -1280.67% | -1780.71% | -1415.68% |
| Biomerica, Inc. (BMRA)vs › | $6.61M | -84.79% | -89.20% | -105.63% | -91.66% |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.60M | -1084.23% | 0.00% | 0.00% | 0.00% |
| Aclarion, Inc. (ACON)vs › | $6.60M | -10978.48% | -12422.83% | -10763.38% | -10131.90% |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.58M | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | -165.80% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 84.49% |
| 2022-09-30 | -255.95% |
| 2022-06-30 | -302.31% |
| 2022-03-31 | -325.46% |
| 2021-12-31 | -652.74% |
| 2021-09-30 | 639.95% |
| 2021-06-30 | -18062.03% |
| 2021-03-31 | -1251.45% |
| 2020-12-31 | -9060.71% |
| 2020-09-30 | -361.11% |
| 2020-06-30 | -88.94% |
| 2020-03-31 | 12.52% |
| 2019-12-31 | -3219.68% |
| 2019-09-30 | -1103.61% |
| 2019-06-30 | -1202.76% |
| 2019-03-31 | -21144.00% |
| 2018-12-31 | -79250.00% |
| 2018-09-30 | -9340.35% |
| 2018-06-30 | -35921.05% |
| 2018-03-31 | -15302.78% |
| 2017-12-31 | -148.07% |
| 2017-09-30 | -77.37% |
| 2017-06-30 | -110.72% |
| 2017-04-01 | -109.05% |
| 2016-12-31 | -817.68% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | -2246.53% |
| 2016-03-31 | -2246.53% |
